Results 161 to 170 of about 145,684 (315)

IBD in the Time of COVID19 [PDF]

Crohn's & Colitis 360, 2020
Moss, Alan, Regueiro, Miguel
openaire   +2 more sources

Immune Checkpoint Inhibitors Induce Intestinal Epithelial Injury and a Senescence‐Like Phenotype

iNew Medicine, EarlyView.
ICI treatment promotes the infiltration of activated immune cells into the intestinal mucosa. This inflammatory microenvironment is associated with significant epithelial injury, characterized by the disruption of the epithelial barrier, the depletion of specialized secretory cell lineages, and the induction of a premature senescence phenotype ...
Juan Wang, Shuang Wu, Shuangbiao Wei, Weizhen Xiang, Jianshang Huang, Lei Xiong, Hua Wang, Li Zuo   +7 more
wiley   +1 more source

Quality metrics reflecting patient experience of gastrointestinal endoscopy in inflammatory bowel disease: results of national endoscopy dataset analysis. [PDF]

J Crohns Colitis
Jones F, Lavelle A, MacCarthy F, Patchett S, Morcos A, Moloney M, Cullen G, Slattery E, Leyden J, O'Morain C, Egan L, Zammarchi I, Iacucci M, Doherty GA.   +13 more
europepmc   +1 more source

Tiny carriers, big impact: How Fusobacterium nucleatum extracellular vesicles drive oral diseases and beyond

Interdisciplinary Medicine, EarlyView.
This review explores how Fusobacterium nucleatum extracellular vesicles drive local oral diseases and distal pathologies via sophisticated cross‐compartment cross talk. It highlights the transformative potential of these “tiny carriers” as next‐generation molecular intermediaries for advanced health monitoring and innovative bio‐interventions by ...
Rongyang Ma, Jiahui Huang, Yitong Chen, Haoxuan Wang, Hang Zou, Wanghong Zhao, Zilong Deng   +6 more
wiley   +1 more source

Crosstalk between circRNAs and the classic signaling pathways in IBD. [PDF]

RNA Biol
Jie M, Liao Q, Liu C.
europepmc   +1 more source

Self-disclosure and disordered eating in inflammatory bowl disease (IBD) [PDF]

Introduction: As Inflammatory Bowel Disease (IBD) is an invisible illness, individuals must make decisions around self-disclosure. Existing reviews have identified stigma as a barrier to disclosing IBD, however, other factors potentially affecting ...
Harriman, E.
core  

Multi‐omics biomarkers for intestinal infection and inflammation in inflammatory bowel disease: Current evidence, translational challenges, and diagnostic opportunities

Interdisciplinary Medicine, EarlyView.
Prospective multi‐site cohorts, multi‐omics profiling, and computational analysis may help identify biomarker patterns across clinical settings in IBD and superimposed infections. With further mechanistic and clinical validation, these signals could support the development of practical multi‐analyte tools for more precise diagnosis and management ...
Ziyu Yang, Jiayi Yao, Xinxian Zhao, Yan Xu, Yifan Chen, Tianchi Chen, Ying Jian, Min Li   +7 more
wiley   +1 more source

Exploration of the in vitro cytotoxic and antiviral activities of different medicinal plants against infectious bursal disease (IBD) virus

Open Life Sciences, 2014
Ahmad Waqas, Ejaz Sohail, Anwar Khaleeq, Ashraf Muhammad   +3 more
doaj   +1 more source

Serum proteomics in paediatric inflammatory bowel disease from a case-control study: biomarker discovery and ulcerative colitis-Crohn's disease differentiation. [PDF]

EBioMedicine
Omede M, Otu HH, Grossberg LB, Huang JY, Gu X, Dillon ST, Can H, Morhardt TL, Pursley C, Winter HS, Libermann TA.   +10 more
europepmc   +1 more source

Deep learning‐assisted design of nanozyme for immune regulation

Journal of Intelligent Medicine, EarlyView.
Overview of nanozyme‐based strategies for inflammatory bowel disease therapy, featuring metal‐based and non‐metallic nanozymes classified by structure, alongside multifunctional and engineered probiotic‐based nanozymes classified by function. Abstract Inflammatory bowel disease (IBD), with rising global incidence and disease burden, is a multifactorial
Ke Chen, Si Sun, Shaofang Zhang, Huanhuan Qiao   +3 more
wiley   +1 more source